



Annual General Meeting

June 2022

Forward Looking Statement

This presentation may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this presentation may include forward looking information relating to the Phase 3 BETonMACE2 clinical trial, Covid-19, vascular cognitive dementia, chronic kidney disease, Fabry disease and pulmonary arterial hypertension clinical trials, and the potential role of apabetalone in the treatment of high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Donald McCaffrey
Email: don@resverlogix.com
Phone: 587-390-8887
Website: www.resverlogix.com



Key Highlights

Apabetalone is a **first-in-class Phase 3 asset** with a demonstrated cardio-protective benefit in high-risk cardiovascular, diabetic, and chronic kidney disease patients – utilizing advanced epigenetics to **regulate expression of multiple disease-causing genes**

FDA Breakthrough Therapy Designation awarded to Apabetalone for prevention of Major Adverse Cardiovascular Events (MACE) in high-risk CVD patients, demonstrating a critical ability to obtain **expedited regulatory approval** for a lead indication

FDA endorsement was based on a Phase 3 study in which Apabetalone demonstrated up to **a 63% hazard reduction**, with a P-value of $p=0.0002$, in MACE and hospitalization for Congestive Heart Failure (CHF) in high-risk CVD patients


Numerous publications, **including Cell and Nature**, have demonstrated the potential of Apabetalone's dual anti-viral and anti-inflammatory approach in preventing and treating the severe and lasting effects of COVID-19

Resverlogix and **EVERSANA™**, a world leader in next generation commercialization, have partnered to **accelerate the commercialization** of Apabetalone for COVID-19 by 2-3 years

With approvals from Health Canada and Brazil, Resverlogix commenced clinical trials of apabetalone in COVID-19. The FDA has granted a **Type C meeting** to advance to Phase 3. Trial **protocol approval is expected to follow** the scheduled meeting (Early August)



Resverlogix: Key Milestones





Clinical Programs: Recent Advancements

We are a global leader in the development of epigenetic therapies for the treatment of chronic disease

Cell

Article

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection

Richard J. Mills¹, Sean J. Humphrey², Patrick R.J. Fortuna¹, Mary Lor¹, Simon R. Foster¹, Gregory A. Quaife-Ryan¹, Rebecca L. Johnston¹, Troy Dumenil¹, Cameron Bishop¹, Rajeev Rudraraju^{3,4,5}, Daniel J. Rawle¹, Thuy Le¹, Wei Zhao⁵, Leo Lee⁵, Charley Mackenzie-Kludas⁵, Neda R. Mehdiabadi⁵, Christopher Halliday⁷, Dean Gilham⁷ ... James E. Hudson^{1,20}  

JAMA | Original Investigation

Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes
A Randomized Clinical Trial

Kausik K. Ray, MBChB; Stephen J. Nicholls, MBBS, PhD; Kevin A. Buhr, PhD; Henry N. Ginsberg, MD; Jan O. Johansson, MD, PhD; Kamyar Kalantar-Zadeh, MD; Ewelina Kulikowski, PhD; Peter P. Toth, MD, PhD; Norman Wong, MD; Michael Sweeney, MD; Gregory G. Schwartz, MD, PhD; for the BETonMACE Investigators and Committees




biomedicines



Article

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro

Dean Gilham^{1,4}, Audrey L. Smith^{2,4}, Li Fu^{1,4}, Dalia Y. Moore², Abenaya Muralidharan³, St. Patrick M. Reid³, Stephanie C. Stotz¹, Jan O. Johansson¹, Michael Sweeney¹, Norman C. W. Wong¹, Ewelina Kulikowski^{1,2} and Dalia El-Gamal^{2,4}

 Cardiovascular Diabetology

Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial

Gregory G. Schwartz¹, Stephen J. Nicholls², Peter P. Toth^{3,4}, Michael Sweeney⁵, Christopher Halliday⁵, Jan O. Johansson⁵, Norman C. W. Wong⁵, Ewelina Kulikowski⁵, Kamyar Kalantar-Zadeh⁶, Henry N. Ginsberg⁷ and Kausik K. Ray⁸

CJASN
Official Journal of the American Society of Nephrology

Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome
Results from the BETonMACE Randomized Controlled Trial

Kamyar Kalantar-Zadeh¹, Gregory G. Schwartz², Stephen J. Nicholls³, Kevin A. Buhr⁴, Henry N. Ginsberg⁵, Jan O. Johansson⁶, Ewelina Kulikowski⁶, Kenneth Lebiada⁶, Peter P. Toth^{7,8}, Norman Wong⁶, Michael Sweeney⁶ and Kausik K. Ray⁹ on behalf of the BETonMACE Investigators

 Cardiovascular Diabetology

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

Stephen J. Nicholls¹, Gregory G. Schwartz², Kevin A. Buhr³, Henry N. Ginsberg⁴, Jan O. Johansson⁵, Kamyar Kalantar-Zadeh⁶, Ewelina Kulikowski⁶, Peter P. Toth^{7,8}, Norman Wong⁶, Michael Sweeney⁶ and Kausik K. Ray⁹ on behalf of the BETonMACE Investigators

 Journal of
Alzheimer's Disease

Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial

Jeffrey Cummings¹, Gregory G. Schwartz², Stephen J. Nicholls³, Aziz Khan⁴, Chris Halliday⁵, Peter P. Toth⁶, Michael Sweeney⁶, Jan O. Johansson⁶, Norman C. W. Wong⁶, Ewelina Kulikowski⁶, Kamyar Kalantar-Zadeh⁶, Kenneth Lebiada⁶, Henry N. Ginsberg⁶, Bengt Winblad⁷, Henrik Zetterberg^{8,9,10} and Kausik K. Ray⁸

RESVERLOGIX

Four Pillars: Therapeutic Product Development



1

Intellectual Property & Academic Support

- Multiple patents
- Coverage to 2040
- Over 40 publications



2

Regulatory Approval Pathway

- Breakthrough Therapy Designation
- Additional indications under review - Type C meeting



3

Commercialization Strategy & Capacity

- Expanded partnership with EVERSANA™
- Detailed COVID-19 commercialization work in place




4

Financing


- Industry-wide downturn nearing 80%
- Alternate non-equity options being pursued

Biotechnology Market: Severe Industry-wide Downturn

Biotech Performance by Market Cap since XBI High (Feb 2021)



Clinical Trial Timelines: Accelerated Development with Interim Analyses



BETonMACE2: Registration Enabling Design

BETonMACE2 will be larger and have a greater concentration of patients in the subgroups where apabetalone has the most benefit



	BETonMACE	BETonMACE2
Sample Size	2418	3600
Low eGFR	12%	25%
SGLT2i or DPP4i	22%	100%
Approximate Cost		\$80MM
Resverlogix Cost		\$40MM +

BETonMACE2: Treating Patients Who Stand to Benefit the Most

BETonMACE Study population


p = 0.03

eGFR < 60 mL/min/1.73m²

p = 0.01

SGLT2i or DPP4i Co-administration

p = 0.0002






COVID-19 Program Update and Progress



The Pandemic Continues to Unfold



Apabetalone can play an important role in preventing negative outcomes in COVID-19



COVID-19 Program: Scientific Advisory Board

- A team of highly engaged, experienced, and respected COVID-19 clinical trial investigators
- Infectious Disease, Critical and Emergency Care Specialists



JUDITH S. CURRIER, MD
Professor of Medicine
Division Chief, Infectious Diseases
Director, UCLA Clinical AIDS
Research and Education
UCLA Health
Los Angeles, California



PRINCY N. KUMAR, MD, FIDSA, MACP
Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and
Tropical Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, District of Columbia



CARLOS DEL RIO, MD
Executive Associate Dean
Distinguished Professor
Emory School of Medicine
Atlanta, Georgia



**TIFFANY M. OSBORN, MD,
MPH, FCCM, FACEP, FAEM**
Professor of Surgery
and Emergency Medicine
Barnes Jewish Hospital
St. Louis, Missouri



FRANCO R. D'ALESSIO, MD
Associate Professor Of Medicine
Johns Hopkins University
Attending Physician
Johns Hopkins Hospital
Baltimore, Maryland



BARRY ZINGMAN, MD
Professor
Albert Einstein College of Medicine
Bronx, New York

Apabetalone in COVID-19: A Unique Dual-mechanism

1

Anti-viral

Apabetalone blocks cellular entry of SARS-CoV-2 by reducing expression of the key receptor ACE2

2

Anti-inflammatory

Apabetalone prevents runaway inflammatory responses to the virus, which drive severe outcomes



biomedicines



Article

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro

Dean Gilham ^{1,†}, Audrey L. Smith ^{2,†}, Li Fu ^{1,†}, Dalia Y. Moore ², Abenaya Muralidharan ³, St. Patrick M. Reid ³, Stephanie C. Stotz ¹, Jan O. Johansson ¹, Michael Sweeney ¹, Norman C. W. Wong ¹, Ewelina Kulikowski ^{1,†} and Dalia El-Gamal ^{2,*}


Cell

Article

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection

Richard J. Mills ¹, Sean J. Humphrey ², Patrick R.J. Fortuna ¹, Mary Lor ¹, Simon R. Foster ¹, Gregory A. Quaife-Ryan ¹, Rebecca L. Johnston ¹, Troy Dumenil ¹, Cameron Bishop ¹, Rajeev Rudraraju ^{3,4,5}, Daniel J. Rawle ¹, Thuy Le ¹, Wei Zhao ⁵, Leo Lee ⁵, Charley Mackenzie-Kludas ⁵, Neda R. Mehdiabadi ⁶, Christopher Halliday ⁷, Dean Gilham ⁷ ... James E. Hudson ^{1,20}

COVID-19: Apabetalone and Disease Progression



We Thrive on Solid Partnership



EVERSANA™



We partnered with EVERSANA™ to support the development of apabetalone. Together, we can leverage our emerging technology platform to help patients worldwide who suffer from chronic disease



Aligned Objectives: EVERSANA™'s Dedicated Commercialization Team





Contact:

Donald McCaffrey, President & CEO

Email: don@resverlogix.com

Phone: 587-390-8887

Website: www.resverlogix.com